PK2 (FCE28069, 27,000 g/mol, 8 wt% DOX; Fig. 3B), the only targeted polymer conjugate containing galactosamine to enter clinical trials, is designed to target the asialoglycoprotein receptor (ASGPR) which is selectively expressed in hepatocytes and hepatoma cell lines (40,72). Here, ASGR1 is linked to hepatocellular carcinoma.